HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ortaldo, J. R. Articles by Wiltrout, R. H. Search for Related Content PubMed PubMed Citation Articles by Ortaldo, J. R. Articles by Wiltrout, R. H.

Dissociation of NKT Stimulation, Cytokine Induction, and NK Activation In Vivo by the Use of Distinct TCR-Binding Ceramides¹

John R. Ortaldo^2,*, Howard A. Young^*, Robin T. Winkler-Pickett^*, Earl W. Bere, Jr.^*, William J. Murphy and Robert H. Wiltrout^*

^* Laboratory of Experimental Immunology, National Cancer Institute-Center for Cancer Research, Frederick, MD 21702; and Department Microbiology, University of Nevada Medical School, Reno, NV 89557

NKT and NK cells are important immune regulatory cells. The only efficient means to selectively stimulate NKT cells in vivo is -galactosylceramide (GalCer). However, GalCer effectively stimulates and then diminishes the number of detectable NKT cells. It also exhibits a potent, indirect ability to activate NK cells. We have now discovered another ceramide compound, -galactosylceramide (GalCer) (C12), that efficiently diminishes the number of detectable mouse NKT cells in vivo without inducing significant cytokine expression or activation of NK cells. Binding studies using CD1d tetramers loaded with GalCer (C12) demonstrated significant but lower intensity binding to NKT cells when compared with GalCer, but both ceramides were equally efficient in reducing the number of NKT cells. However, GalCer (C12), in contrast to GalCer, failed to increase NK cell size, number, and cytolytic activity. Also in contrast to GalCer, GalCer (C12) is a poor inducer of IFN-, TNF-, GM-CSF, and IL-4 gene expression. These qualitative differences in NKT perturbation/NK activation have important implications for delineating the unique in vivo roles of NKT vs NK cells. Thus, GalCer (which triggers NKT cells and activates NK cells) efficiently increases the resistance to allogeneic bone marrow transplantation while GalCer (C12) (which triggers NKT cells but does not activate NK cells) fails to enhance bone marrow graft rejection. Our results show GalCer (C12) can effectively discriminate between NKT- and NK-mediated responses in vivo. These results indicate the use of different TCR-binding ceramides can provide a unique approach for understanding the intricate immunoregulatory contributions of these two cell types.

This article has been cited by other articles:

				R. Geiben-Lynn, J. R. Greenland, K. Frimpong-Boateng, and N. L. Letvin Non-classical Natural Killer T Cells Modulate Plasmid DNA Vaccine Antigen Expression and Vaccine-elicited Immune Responses by MCP-1 Secretion after Interaction with a {beta}2-Microglobulin-independent CD1d J. Biol. Chem., December 4, 2009; 284(49): 33800 - 33806. [Abstract] [Full Text] [PDF]

				G. Lalazar, A. B. Ya'acov, D. M. Livovsky, M. El Haj, O. Pappo, S. Preston, L. Zolotarov, and Y. Ilan {beta}-Glycoglycosphingolipid-Induced Alterations of the STAT Signaling Pathways Are Dependent on CD1d and the Lipid Raft Protein Flotillin-2 Am. J. Pathol., April 1, 2009; 174(4): 1390 - 1399. [Abstract] [Full Text] [PDF]

				G. Lalazar, A. Ben Ya'acov, N. Eliakim-Raz, D. M. Livovsky, O. Pappo, S. Preston, L. Zolotarov, and Y. Ilan {beta}-Glycosphingolipids-mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping J. Lipid Res., September 1, 2008; 49(9): 1884 - 1893. [Abstract] [Full Text] [PDF]

				T. Ebensen, C. Link, P. Riese, K. Schulze, M. Morr, and C. A. Guzman A Pegylated Derivative of {alpha}-Galactosylceramide Exhibits Improved Biological Properties J. Immunol., August 15, 2007; 179(4): 2065 - 2073. [Abstract] [Full Text] [PDF]

				J. J. Subleski, V. L. Hall, T. C. Back, J. R. Ortaldo, and R. H. Wiltrout Enhanced Antitumor Response by Divergent Modulation of Natural Killer and Natural Killer T Cells in the Liver. Cancer Res., November 15, 2006; 66(22): 11005 - 11012. [Abstract] [Full Text] [PDF]

				R. R. Brutkiewicz CD1d Ligands: The Good, the Bad, and the Ugly J. Immunol., July 15, 2006; 177(2): 769 - 775. [Abstract] [Full Text] [PDF]

				L. Kjer-Nielsen, N. A. Borg, D. G. Pellicci, T. Beddoe, L. Kostenko, C. S. Clements, N. A. Williamson, M. J. Smyth, G. S. Besra, H. H. Reid, et al. A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition J. Exp. Med., March 20, 2006; 203(3): 661 - 673. [Abstract] [Full Text] [PDF]

				S. Oki, C. Tomi, T. Yamamura, and S. Miyake Preferential Th2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo Int. Immunol., December 1, 2005; 17(12): 1619 - 1629. [Abstract] [Full Text] [PDF]

				J. R. Ortaldo, R. T. Winkler-Pickett, E. W. Bere Jr, M. Watanabe, W. J. Murphy, and R. H. Wiltrout In Vivo Hydrodynamic Delivery of cDNA Encoding IL-2: Rapid, Sustained Redistribution, Activation of Mouse NK Cells, and Therapeutic Potential in the Absence of NKT Cells J. Immunol., July 15, 2005; 175(2): 693 - 699. [Abstract] [Full Text] [PDF]

				T. Ota, K. Takeda, H. Akiba, Y. Hayakawa, K. Ogasawara, Y. Ikarashi, S. Miyake, H. Wakasugi, T. Yamamura, M. Kronenberg, et al. IFN-{gamma}-mediated negative feedback regulation of NKT-cell function by CD94/NKG2 Blood, July 1, 2005; 106(1): 184 - 192. [Abstract] [Full Text] [PDF]

				M. J. Smyth, M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer J. Exp. Med., June 20, 2005; 201(12): 1973 - 1985. [Abstract] [Full Text] [PDF]

				J. S. Bezbradica, A. K. Stanic, N. Matsuki, H. Bour-Jordan, J. A. Bluestone, J. W. Thomas, D. Unutmaz, L. Van Kaer, and S. Joyce Distinct Roles of Dendritic Cells and B Cells in Va14Ja18 Natural T Cell Activation In Vivo J. Immunol., April 15, 2005; 174(8): 4696 - 4705. [Abstract] [Full Text] [PDF]

				V. V. Parekh, A. K. Singh, M. T. Wilson, D. Olivares-Villagomez, J. S. Bezbradica, H. Inazawa, H. Ehara, T. Sakai, I. Serizawa, L. Wu, et al. Quantitative and Qualitative Differences in the In Vivo Response of NKT Cells to Distinct {alpha}- and {beta}-Anomeric Glycolipids J. Immunol., September 15, 2004; 173(6): 3693 - 3706. [Abstract] [Full Text] [PDF]

				J. E. Gumperz CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? J. Leukoc. Biol., August 1, 2004; 76(2): 307 - 313. [Abstract] [Full Text] [PDF]

				Y. Campos-Martin, M. Gomez del Moral, B. Gozalbo-Lopez, J. Suela, and E. Martinez-Naves Expression of Human CD1d Molecules Protects Target Cells from NK Cell-Mediated Cytolysis J. Immunol., June 15, 2004; 172(12): 7297 - 7305. [Abstract] [Full Text] [PDF]